Stock Price
351.96
Daily Change
0.16 0.05%
Monthly
-11.53%
Yearly
27.38%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $2.9 in EPS Earnings Per Share for its fiscal quarter ending in September of 2025.


Fiscal Calendar Actual Consensus Previous Date
FY2025Q4 Dec/2025 1.27 0.06 Feb/12 2026
FY2025Q3 Sep/2025 2.90 0.27 -0.50 Oct/30 2025
FY2025Q2 Jun/2025 0.32 -0.73 0.56 Jul/31 2025
FY2025Q1 Mar/2025 -0.01 -0.94 -0.16 May/01 2025
FY2024Q4 Dec/2024 0.06 -0.58 -0.77 Feb/13 2025




Eps Change Date
Acadia Pharmaceuticals USD 0.42 0.26 Sep/2025
Agios Pharmaceuticals USD -1.78 0.15 Sep/2025
Alnylam Pharmaceuticals USD 2.9 2.58 Sep/2025
Amgen USD 5.29 0.35 Dec/2025
Arrowhead Research USD -0.11 1.15 Sep/2025
BioMarin Pharmaceutical USD 0.12 1.32 Sep/2025
Incyte USD 2.26 0.69 Sep/2025
Ionis Pharmaceuticals USD -0.8 1.5 Sep/2025
Moderna USD -0.51 1.62 Sep/2025
Neurocrine Biosciences USD 2.17 0.52 Sep/2025
Novartis USD 2.02 0.04 Sep/2025
PTC Therapeutics USD 0.2 1.03 Sep/2025
Regeneron Pharmaceuticals USD 11.44 0.39 Dec/2025
Sanofi EUR -0.67 3.62 Dec/2025
Sarepta Therapeutics USD -0.13 2.15 Sep/2025
Takeda JPY 65.74 73.57 Dec/2025
Tectonic Therapeutic USD -1.02 0.05 Sep/2025
Ultragenyx Pharmaceutical USD -1.81 0.64 Sep/2025
Vertex Pharmaceuticals USD 4.8 0.28 Sep/2025
Xencor USD -0.08 0.33 Sep/2025